Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Receivables (2016 - 2025)

CorMedix's Change in Receivables history spans 10 years, with the latest figure at $12.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 63.97% year-over-year to $12.4 million; the TTM value through Dec 2025 reached $90.9 million, up 76.26%, while the annual FY2025 figure was $90.9 million, 75.56% up from the prior year.
  • Change in Receivables for Q4 2025 was $12.4 million at CorMedix, down from $87.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $87.3 million in Q3 2025 and bottomed at -$11.7 million in Q2 2025.
  • The 4-year median for Change in Receivables is $21337.0 (2021), against an average of $10.2 million.
  • The largest YoY upside for Change in Receivables was 1825.73% in 2021 against a maximum downside of 1290.7% in 2021.
  • A 4-year view of Change in Receivables shows it stood at $47354.0 in 2021, then crashed by 99.07% to $440.0 in 2022, then surged by 7818889.55% to $34.4 million in 2024, then plummeted by 63.97% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Change in Receivables are $12.4 million (Q4 2025), $87.3 million (Q3 2025), and -$11.7 million (Q2 2025).